GIANAKAKOS ANASTASIOS

Form 4

February 22, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

0.5

OMB APPROVAL

Form 4 or Form 5 obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

burden hours per response...

Estimated average

may continue. See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * GIANAKAKOS ANASTASIOS			2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer	
			MAP Pharmaceuticals, Inc. [MAPP]	(Check all applicable)	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction		
			(Month/Day/Year)	Director 10% Owner	
2400 BAYSHORE PARKWAY, SUITE 200			02/21/2012	_X_ Officer (give title Other (specify below)	
				SVP & Chief Business Officer	
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check	
			Filed(Month/Day/Year)	Applicable Line)	
MOUNTAIN VIEW, CA 94043				_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of 6. 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Ownership Indirect (Instr. 3) (Instr. 3, 4 and 5) Beneficially Code Form: Beneficial (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (A) Transaction(s) (Instr. 4) (Instr. 3 and 4) Code V Amount Price Common 02/21/2012 M 1,115 A \$ 6.3897 13,500 D Stock \$ Common 02/21/2012 $S^{(1)}$ 1.115 D 16.0218 12,385 D Stock (2) Common 02/21/2012 M 1,385 A \$ 6.3897 13,770 D Stock \$ Common 02/21/2012 $S^{(1)}$ 1,385 D 15.9948 12,385 D Stock

Edgar Filing: GIANAKAKOS ANASTASIOS - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 8. I De Sec (In

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number conf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and Underlying (Instr. 3 and	Securities	8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 6.3897	02/21/2012		M	1,115	(3)	05/01/2017	Common Stock	1,115	
Stock Option (Right to Buy)	\$ 6.3897	02/21/2012		M	1,385	(3)	05/01/2017	Common Stock	1,385	

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
GIANAKAKOS ANASTASIOS 2400 BAYSHORE PARKWAY, SUITE 200 MOUNTAIN VIEW, CA 94043			SVP & Chief Business Officer		

Date

Signatures

**Signature of Reporting Person

/s/ Anastasios E.	02/22/2012
Gianakakos	02/22/2012

Reporting Owners 2

Edgar Filing: GIANAKAKOS ANASTASIOS - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale of the reported shares is made pursuant to terms of 10b5-1 plan in effect at the time of sale of the shares.
 - The range of price is from \$15.87 to \$16.29 per share. Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, or a security holder of the issuer. The range of price is from \$15.87 to \$16.29 per share. Full
- (2) information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, or a security holder of the issuer. The range of price is from \$15.87 to \$16.29 per share. Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, or a security holder of the issuer.
- The option is exercisable as it vests: 25% of the total number of option shares vests and becomes exercisable on the first anniversary of the vesting commencement date. Thereafter, 1/48th of the total number of option shares becomes exercisable cumulatively on each monthly anniversary for 36 months so that the entire number of option shares becomes fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.